RA Capital Management led a $35m Series D in Vivace Therapeutics.

RA Capital Management, an investment firm, led a $35m Series D in Vivace Therapeutics, a biotechnology research company, with participation from Canaan Partners and Cenova Capital. "The results of our clinical evaluation of VT3989 to date give us confidence that the appropriate next step for the program is advancement into a registrational Phase 3 trial in patients with mesothelioma. We are now laser focused on executing against this strategy, including completing our ongoing clinical study and meeting with FDA to align on next steps. We are grateful to RA Capital for leading this round, as well as the continued support from Canaan Partners and Cenova Capital. This new funding will prove critical to enabling our successful development of VT3989," Sofie Qiao, Vivace Therapeutics President and CEO.